Los Angeles has been a major epicenter of the AIDS epidemic since the first cases of this disease were reported from UCLA in 1981. Over the last 29 years, both UCLA and USC have been major centers for research in HIV/AIDS and were two ofthe first institutions to become heavily involved in the treatment of pafients with AIDS related malignancies. These two institufions have chosen to form a combined AMC core site each with its unique strengths and leadership for the Group and to provide two locations where the diverse HIV populafion of Los Angeles may access AMC trials. The 2 institutions complement each others in their primary areas expertise and major disease populafions and trials enrollment. UCLA has primary interest and expertise in HPV, lymphoma and NADC while USC has chosen to focus more on KS, lymphoma and NADC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA121947-07
Application #
8549964
Study Section
Special Emphasis Panel (ZCA1-SRLB-D)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$584,310
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Barta, Stefan K; Joshi, Jitesh; Mounier, Nicolas et al. (2016) Central nervous system involvement in AIDS-related lymphomas. Br J Haematol 173:857-66
Gopal, Satish; Fedoriw, Yuri; Kaimila, Bongani et al. (2016) CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi. PLoS One 11:e0150445
Alvarnas, Joseph C; Le Rademacher, Jennifer; Wang, Yanli et al. (2016) Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood 128:1050-8
Epeldegui, Marta; Lee, Jeannette Y; Martínez, Anna C et al. (2016) Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res 22:328-36
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Hernandez, Alexandra L; Karthik, Rajiv; Sivasubramanian, Murugesan et al. (2016) Prevalence of Anal HPV Infection Among HIV-Positive Men Who Have Sex With Men in India. J Acquir Immune Defic Syndr 71:437-43
Montgomery, Nathan D; Liomba, N George; Kampani, Coxcilly et al. (2016) Accurate Real-Time Diagnosis of Lymphoproliferative Disorders in Malawi Through Clinicopathologic Teleconferences:  A Model for Pathology Services in Sub-Saharan Africa. Am J Clin Pathol 146:423-30
Willeford, Wesley G; Bachmann, Laura H (2016) Uncertainty Abounds in the World of Anal Dysplasia Screening. Sex Transm Dis 43:436-7
Bender Ignacio, Rachel A; Lee, Jeannette Y; Rudek, Michelle A et al. (2016) Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr 72:52-7
Noy, Ariela; Lensing, Shelly Y; Moore, Page C et al. (2016) Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. Leuk Lymphoma 57:1731-4

Showing the most recent 10 out of 105 publications